Pluristem's PLX Cells Demonstrate Efficacy in Preclinical Study for Graft versus Host Disease

Pluristem's PLX Cells Demonstrate Efficacy in Preclinical Study for Graft
versus Host Disease

    Both Intramuscular and Intravenous Administrations Show Statistically
                           Significant Improvement

      Clinical Path Being Investigated With Leading Medical Institutions

HAIFA, Israel, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today that the company's PLacental eXpanded (PLX) cells
demonstrated efficacy in a preliminary animal experiment for the treatment of
Graft versus Host Disease (GvHD) following bone marrow transplantation (BMT).
The results showed that PLX cells, regardless of their administration route,
intravenous (IV) or intramuscular (IM), demonstrated a statistically
significant improvement (p < 0.05) in the GvHD score. Following interest from
leading medical institutions, Pluristem is investigating a potential
cooperation to bring this indication to a clinical trial.

GvHD may occur after BMT when patients receive bone marrow tissue or cells
from a donor and these newly transplanted cells regard the recipient's body as
foreign, attacking the recipient's body. The global incidence of acute GvHD
ranges from 26% to 34% in recipients of fully matched sibling donor grafts, to
42% to 52% in recipients of matched unrelated donor grafts.

The animal study was conducted in the laboratories of the Department of Bone
Marrow Transplantation, Hadassah Medical Center, the Hebrew University,
Jerusalem.

In the study, mice underwent total body irradiation and after twenty-four
hours received a semi-allogeneic BMT. PLX cells, or the same volumes of the
control vehicle, were then injected IV or IM into the mice concurrently with
the BMT (day 0, ~20h after irradiation) and 5 days post-irradiation. PLX
markedly reduced the GvHD score, comprised of weight loss, diarrhea, skin and
fur integrity and survival. This significant (p < 0.05) reduction in the GvHD
score occurred in both the IV and IM treatment groups 42 days after
transplantation. Moreover, histological examination of the liver revealed
reduced hepatic lymphocyte infiltration, a marker for the severity of GvHD
occurring in the PLX-treated groups without preference to the route of
administration.

"Based on the results of this pre clinical study suggesting our PLX cells may
be effective in GvHD, we are pleased with the interest of leading medical
institutions to use our PLX cells and will consider a cooperation to advance
into a clinical program for this indication," said Zami Aberman, Chairman and
CEO of Pluristem. "This indication would be complementary to the other
indications we plan to pursue in the hematology field. Additionally, this
study also gives Pluristem another data point demonstrating PLX cells do not
have to be given intravenously to obtain a systemic effect."

IM Administration with Systemic Effect

This preclinical study marks the second time that the IM administration of PLX
cells has demonstrated a systemic effect with efficacy in a hematological
disease and the fourth time when preclinical animal models for other
indications are included. Pluristem previously reported that the IM injection
of PLX cells demonstrated a systemic effect in preclinical studies of
Peripheral Artery Disease (PAD), Preeclampsia and Acute Radiation Sickness
(ARS). Additionally, systemic, beneficial effects were also noted in three
patients given PLX cells IM compassionately for Bone Marrow Failure.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell
therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug
delivery platform that releases a cocktail of therapeutic proteins in response
to a host of local and systemic inflammatory and ischemic diseases. PLX cells
are grown using the company's proprietary 3D micro-environmental technology
and are an "off-the-shelf" product that requires no tissue matching prior to
administration.

Pluristem has a strong intellectual property position, company-owned GMP
certified manufacturing and research facilities, strategic relationships with
major research institutions and a seasoned management team. For more
information visit www.pluristem.com, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=6882

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, when we discuss that the
results of this pre clinical study suggest our PLX cells may be effective in
GvHD, or that we will consider a cooperation to advance into a clinical
program for GvHD, or that we plan to pursue other indications in the
hematology field, we are using forward-looking statements. These
forward-looking statements and their implications are based on the current
expectations of the management of Pluristem only, and are subject to a number
of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. The
following factors, among others, could cause actual results to differ
materially from those described in the forward-looking statements: changes in
technology and market requirements; we may encounter delays or obstacles in
launching and/or successfully completing our clinical trials; our products may
not be approved by regulatory agencies, our technology may not be validated as
we progress further and our methods may not be accepted by the scientific
community; we may be unable to retain or attract key employees whose knowledge
is essential to the development of our products; unforeseen scientific
difficulties may develop with our process; our products may wind up being more
expensive than we anticipate; results in the laboratory may not translate to
equally good results in real surgical settings; results of preclinical studies
may not correlate with the results of human clinical trials; our patents may
not be sufficient; our products may harm recipients; changes in legislation;
inability to timely develop and introduce new technologies, products and
applications; loss of market share and pressure on pricing resulting from
competition, which could cause the actual results or performance of Pluristem
to differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Pluristem undertakes no
obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem, reference is
made to Pluristem's reports filed from time to time with the Securities and
Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
        
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         1-303-883-4954
         William.PratherMD@pluristem.com
        
         Daya Lettvin
         Investor & Media Relations Director
         +972-54-674-5580
         daya@pluristem.com

Pluristem Therapeutics Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.